 Syndecan-1
"Syndecan-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A syndecan that interacts with EXTRACELLULAR MATRIX PROTEINS and plays a role CELL PROLIFERATION and CELL MIGRATION.
| Descriptor ID |
D053668
|
| MeSH Number(s) |
D12.776.395.550.847.100 D12.776.395.650.350.500.100 D12.776.543.550.847.100 D23.050.301.264.035.916 D23.101.100.110.940
|
| Concept/Terms |
Syndecan-1- Syndecan-1
- Syndecan 1
- CD138 Antigens
- Antigens, CD138
- CD138 Antigen
- Antigen, CD138
|
Below are MeSH descriptors whose meaning is more general than "Syndecan-1".
Below are MeSH descriptors whose meaning is more specific than "Syndecan-1".
This graph shows the total number of publications written about "Syndecan-1" by people in UAMS Profiles by year, and whether "Syndecan-1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 0 | 2 | 2 | | 2020 | 0 | 2 | 2 | | 2017 | 0 | 1 | 1 | | 2014 | 0 | 2 | 2 | | 2013 | 0 | 4 | 4 | | 2012 | 0 | 1 | 1 | | 2010 | 1 | 1 | 2 | | 2007 | 2 | 0 | 2 | | 2006 | 1 | 1 | 2 | | 2005 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2003 | 0 | 6 | 6 | | 2002 | 0 | 3 | 3 | | 2001 | 0 | 2 | 2 | | 2000 | 0 | 2 | 2 | | 1999 | 0 | 3 | 3 | | 1997 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Syndecan-1" by people in Profiles over the past ten years.
-
Boyle EM, Rosenthal A, Wang Y, Farmer P, Rutherford M, Ashby C, Bauer M, Johnson SK, Wardell CP, Hoering A, Schinke C, Thanendrarajan S, Zangari M, Barlogie B, Davies FE, Walker BA, van Rhee F, Morgan GJ. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. Br J Haematol. 2021 10; 195(2):283-286.
-
Wong KY, Morgan GJ, Boyle EM, Cheng ASL, Yip KY, Chim CS. A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma. Sci Rep. 2021 03 26; 11(1):7009.
-
Chen J, Gao XM, Zhao H, Cai H, Zhang L, Cao XX, Zhou DB, Li J. A highly heterogeneous mutational pattern in POEMS syndrome. Leukemia. 2021 04; 35(4):1100-1107.
-
Dhodapkar MV, Sexton R, Hoering A, Van Rhee F, Barlogie B, Orlowski R. Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. Clin Cancer Res. 2020 11 15; 26(22):5814-5819.
-
Xia J, Xu H, Zhang X, Allamargot C, Coleman KL, Nessler R, Frech I, Tricot G, Zhan F. Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid. EBioMedicine. 2017 Apr; 18:41-49.
-
van Laar R, Flinchum R, Brown N, Ramsey J, Riccitelli S, Heuck C, Barlogie B, Shaughnessy JD. Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use. BMC Med Genomics. 2014 May 17; 7:25.
-
Smetana J, Dementyeva E, Kryukov F, Nemec P, Greslikova H, Kupska R, Mikulasova A, Ihnatova I, Hajek R, Kuglik P. Incidence of cytogenetic aberrations in two B lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH. Neoplasma. 2014; 61(1):48-55.
-
Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD, Hoering A, Crowley J, Orlowski RZ, Barlogie B. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014 Jan 02; 123(1):78-85.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|